Enoxaparin as Prophylaxis against Thromboembolism after Total Hip Replacement

To the Editor: We are concerned about the report of Bergqvist et al. (Sept. 5 issue)¹ and the implications it may have for patient care. They reported that among patients who had total hip arthroplasty, the rate of venography-confirmed deep-vein thrombosis was substantially reduced in those who had continuing prophylaxis with the low-molecular-weight heparin enoxaparin after hospital discharge, compared with a control group that received enoxaparin prophylaxis only while hospitalized. Although we do not question the validity of these findings, we do challenge the clinical significance of the results.